ono、Opdivo Plus Yervoy Combination Demonstrated Superior Overall Survival and Showed Durable Responses in Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma ono、Opdivo Plus Yervoy Combina Wednesday September 13th, 2017By Tokio X'press JPN, Pharmaceutical ONO ono、Opdivo Plus Yervoy Combina
CONCLUSION OF DEVELOPMENT COLLABORATION AGREEMENT FOR OPDIVO® (NIVOLUMAB) AND LENVIMA® (LENVATINIB MESYLATE) COMBINATION THERAPY FOR TREATMENT OF HEPATOCELLULAR CARCINOMA 20170908 CONCLUSION OF DEVELOPMENT COLL Friday September 8th, 2017By Tokio X'press JPN, Pharmaceutical ONO CONCLUSION OF DEVELOPMENT COLL
Drugmaker Eli Lilly to cut 3,500 jobs Drugmaker Eli Li Friday September 8th, 2017By Tokio X'press Pharmaceutical, USA Eli Lilly Drugmaker Eli Li
Takeda and Noile-Immune Biotech Collaborate to Advance Next Generation CAR-T Cell Therapy Effective for Solid Tumors Takeda and Noile-Immune Biotec Tuesday September 5th, 2017By Tokio X'press JPN, Pharmaceutical Takeda Takeda and Noile-Immune Biotec
Long-Term Analysis of Phase 3 Head-To-Head Study Confirms KYPROLIS® (Carfilzomib) Regimen Extends Overall Survival in Patients with Relapsed Multiple Myeloma News Release 20170901 Long-Term Analysis of Phase 3 Saturday September 2nd, 2017By Tokio X'press JPN, Pharmaceutical ONO Long-Term Analysis of Phase 3
